newsfilter
← Latest News
Business Wire·

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design